Trevena Inc TRVN

Healthcare Biotechnology

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of medicines for patients with central nervous system (CNS) disorders. The Company has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s pipeline includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. TRV734 is a small molecule G-protein biased ligand of the mu opioid receptor (MOR).

OTCPK:TRVN - Post by User

Trevena Inc

Bullboard Posts

Post by jagsfan2on May 30, 2017 10:38am

58 Views

Post# 26300143

Getting down there ...

..... falling as steadily as DJ Trump.

Getting closer to my sort of range but the major stock markets have eyt to burst their bubble.
US$2.62 right now & I figured if/when the bubble bursts I'd maybe dabble if its close to $2.20.
Hard to put a real value on a stock like this.

GL, as always.

Bullboard Posts

Cannara reports record growth and profitability in Q4 2023